ArticlePediatric nephrology (Berlin, Germany)2026
Plasma-saliva correlations for total and unbound mycophenolic acid and its glucuronide in children with nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pre-Analytical Stability of Mycophenolic Acid and Its Glucuronide in Saliva Samples Stored in Cotton SalivettePharmaceutics · 2026Article
- Population pharmacokinetics of total and free mycophenolic acid in plasma in paediatric patients with nephrotic syndrome including salivary concentrations and the pharmacodynamics.Pharmacological reports : PR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFor mycophenolic acid (MPA), therapeutic drug monitoring (TDM) is recommended due to its complex pharmacokinetics. A non-invasive TDM approach using saliva is promising due to its simplicity and minimal invasiveness. This study investigated the relationship between MPA and its glucuronide metabolite (MPAG) levels in saliva and plasma in children with nephrotic syndrome (NS).
methodsSalivary MPA (sMPA) and MPAG (sMPAG), as well as total MPA (tMPA), total MPAG (tMPAG), and free MPA (fMPA) in plasma were determined for 23 children aged 4-17 years with NS. All children were treated with mycophenolate mofetil twice daily at the same morning and evening doses based on body surface area. Saliva and blood samples were collected before the next dose (C
resultsThe concentration-time profiles showed a similar course for tMPA, sMPA, and fMPA, with the highest variability observed for sMPA. The mean C
conclusionsSaliva may represent a promising matrix for MPA TDM in children with NS, as sMPA and sMPAG generally reflected plasma levels. However, salivary pharmacokinetics exhibited considerable variability, and C
Indexed as
Identifiers
41575524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.